In addition to SERENA-2, SERENA-4 (NCT04711252) is comparing camizestrant and palbociclib versus anastrozole and palbociclib as first-line treatment for women with ER+/HER2– advanced breast cancer. This evidence concerns the gene ERBB2 and breast cancer.